Olaparib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Olaparib and local guidelines before prescribing.

PARP inhibitor

Mechanism

PARP inhibitor.

Uses

BRCA-mutated ovarian, breast, prostate and pancreatic cancer.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Anaemia, nausea, fatigue, myelodysplasia, pneumonitis, VTE.

Interactions

CYP3A4 inhibitors and inducers.

Contraindications and cautions

Pregnancy

Monitoring

FBC

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Reduce dose in moderate renal impairment

Overdose and reversal

Supportive

Special advice

FBC monthly; confirm BRCA status.

More from the textbook: uses, cautions and other points
Where it is discussed in the book